,18 To identify SDL interactions of PLK1 and exploit them in cancer therapeutics, we selected an inducible system37 for expressing a constitutively active PLK1-S137D mutant in HCT116 cells (HCT116-PLK1, Figure 1B). Here, PLK1 is linked to cancer.